Dr. Thomas Kirn, MD, PHD, Rutgers Robert Wood Johnson Medical School, and Dr. Jonathan D. Edwards, Pharm.D., BCPS (AQ-ID), BCGP, Huntsville Hospital, discussed the economic and clinical benefits of the T2 Biosystems’ direct-from-whole blood tests at their hospitals in the ASM 2017 showcase: “Managing Sepsis in the Golden Hour: Controlling Costs and Improving Patient Care through Diagnostic Testing.”
Watch the full presentation below or highlights here.
“With the T2Sepsis Solution, our hospital is not only reducing the use of antifungal therapy, we’re also identifying far more infected patients than was possible with blood culture,” said Dr. Edwards.
Dr. Edwards reported the following findings from Huntsville Hospital:
Dr. Thomas Kirn reported that Robert Wood Johnson Medical School is including the T2Candida Panel as a standard order in their sepsis protocol. Dr. Kirn reported that:
Dr. Kirn also presented preliminary information about Robert Wood Johnson Medical School’s experience as part of the T2Bacteria pivotal trial. Dr. Kirn reported that initial data generated at their institution suggest that the T2Bacteria Panel may be identifying patients that would likely be missed by blood culture due to its insensitivity.
In the Science and Industry Showcase, “Application of Rapid, Blood Culture-Free Diagnostics in the Emergency Department: Improving the Signal to Noise Ratio,” Dr. Mitchell J. Cohen, M.D., Director of Surgery at the Denver Health and the University of Colorado School of Medicine, discussed the important role T2 Biosystems’ diagnostics may play in the emergency department.
Watch the full video below or highlights here.
“In the emergency department, rapid and precise results are critical to triage, treat, and make admission decisions in the best interest of the patient,” said Dr. Cohen. “The T2Sepsis Solution has the potential to provide the rapid results and high sensitivity necessary to make it a valuable tool for the management of infections that lead to sepsis in the ED.”
Dr. Cohen reported that T2Bacteria can be easily integrated in the emergency department setting due to its rapid turnaround time, while blood culture-reliant tests cannot.
T2 Biosystems
101 Hartwell Avenue
Lexington, MA 02421
Phone: 781-457-1200
Fax: 781-357-3080
T2 Biosystems, an emerging leader in the field of in vitro diagnostics, is dedicated to saving lives and reducing the cost of healthcare by empowering clinicians to effectively treat patients faster than ever before. T2 Biosystems is focused on addressing critical unmet needs in healthcare starting with sepsis, one of the deadliest and most expensive conditions in hospitals today.
The T2Dx Instrument, the T2Bacteria and T2Candida Panels have received marketing authorization from the U.S. Food and Drug Administration. All other T2 Biosystems products are considered investigational and for research use only.
T2 Biosystems®, T2MR®, T2Bacteria®, T2Candida®, T2Resistance® and T2Dx® are registered trademarks of T2 Biosystems, Inc. “T2Biosystems” and the T2 Biosystems, Inc. logo design are registered trademarks or trademarks of T2Biosystems, Inc. All software and documentation is subject to T2 Biosystems, Inc. copyrights. All rights reserved. T2Direct Diagnostics™, T2HemoStat™, T2Plex™, T2Cauris™, T2Lyme™ and T2SARS-CoV-2™ are trademarks of T2 Biosystems, Inc.
© 2024 T2 Biosystems, Inc.
Please tell us where you are visiting from: United States | Outside the United States
